All In Biotech

Drug Trial Radar · NCT06677710

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

34

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Dec 31, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Indapta Therapeutics, INC.Industry
Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.

Conditions

  • Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis (PPMS)
  • Secondary Progressive Multiple Sclerosis (SPMS)
  • Non-Active Secondary Progressive Multiple Sclerosis
  • Non-Active SPMS
  • Autoimmune Diseases of the Nervous System
  • Nervous System Diseases
  • Autoimmune Diseases
  • Demyelinating Diseases
  • Immune System Diseases
  • Demyelinating Autoimmune Diseases, Central Nervous System (CNS)

Interventions

  • IDP-023Drug

    NK cell therapy

  • OcrelizumabDrug

    Anti-CD20 antibody therapy

  • Interleukin-2Drug

    Immune cytokine

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy

  • FludarabineDrug

    Lymphodepleting chemotherapy

  • MesnaDrug

    Chemoprotectant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEs and SAEs - (Part 1)Time frame: 1 year
  2. Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with IL-2 and Ocrelizumab (Part 1)Time frame: up to 21 days
  3. Change in cellular response of autoreactive immune cells to antigen (Part 2)Time frame: 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California

  • University of Colorado Hospital

    Aurora, Colorado

  • AdventHealth Orlando - Adventist Health System/Sunbelt, Inc.

    Orlando, Florida

  • Kansas University Medical Center

    Kansas City, Kansas

  • Washington University in St. Louis

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.